IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news ...
Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price.
Battling to regain its market share over rival Eli Lilly, Novo Nordisk announced Tuesday that it will reduce the list prices of its popular weight loss drug Wegovy and diabetes drugs Ozempic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results